{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T10:04:20Z","timestamp":1753869860217,"version":"3.41.2"},"reference-count":12,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T00:00:00Z","timestamp":1633305600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Blood & Cancer"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1002\/pbc.29390","type":"journal-article","created":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T06:23:17Z","timestamp":1633587797000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Programmed cell death protein blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation in an adolescent patient"],"prefix":"10.1002","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4869-8818","authenticated-orcid":false,"given":"Irtiza","family":"Sheikh","sequence":"first","affiliation":[{"name":"Division of Pediatrics and Patient Care The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesar","family":"Nunez","sequence":"additional","affiliation":[{"name":"Division of Pediatrics and Patient Care The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2297-9670","authenticated-orcid":false,"given":"David","family":"McCall","sequence":"additional","affiliation":[{"name":"Division of Pediatrics and Patient Care The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6411-8353","authenticated-orcid":false,"given":"Michael","family":"Roth","sequence":"additional","affiliation":[{"name":"Division of Pediatrics and Patient Care The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Branko","family":"Cuglievan","sequence":"additional","affiliation":[{"name":"Division of Pediatrics and Patient Care The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,10,4]]},"reference":[{"key":"e_1_2_1_3_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27033"},{"key":"e_1_2_1_3_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.278"},{"key":"e_1_2_1_3_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.197"},{"key":"e_1_2_1_3_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-07-861641"},{"key":"e_1_2_1_3_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.e19012"},{"key":"e_1_2_1_3_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-NB2017-044"},{"key":"e_1_2_1_3_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1199310"},{"key":"e_1_2_1_3_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.3467"},{"key":"e_1_2_1_3_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00005-X"},{"key":"e_1_2_1_3_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000215"},{"key":"e_1_2_1_3_12_1","unstructured":"National Cancer Institute National Institutes of Health US Department of Health and Human Services.Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Published November 27 2017. Accessed August 13 2021.https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf"},{"key":"e_1_2_1_3_13_1","unstructured":"Keytruda (Pembrolizumab).Package insert. Merck Sharp & Dohme Corp. U.S. Food and Drug Administration. Revised March 2021. Accessed August 13 2021.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125514s096lbl.pdf"}],"container-title":["Pediatric Blood & Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.29390","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pbc.29390","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.29390","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T06:22:16Z","timestamp":1693203736000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.29390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,4]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1002\/pbc.29390"],"URL":"https:\/\/doi.org\/10.1002\/pbc.29390","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"type":"print","value":"1545-5009"},{"type":"electronic","value":"1545-5017"}],"subject":[],"published":{"date-parts":[[2021,10,4]]},"assertion":[{"value":"2021-08-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e29390"}}